Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
Pittock SJ, Barnett M, Bennett JL, Berthele A, de Sèze J, Levy M, Nakashima I, Oreja-Guevara C, Palace J, Paul F, Pozzilli C, Yountz M, Allen K, Mashhoon Y, Kim HJ.
Ann Neurol. 2023 Jun;93(6):1053-1068. doi: 10.1002/ana.26626. Epub 2023 Apr 5.
PMID:36866852
Role of C5 inhibitors in neuromyelitis optica spectrum disorders with seropositive anti-aquaporin-4 antibody: A systematic review and meta-analysis.
Makkawi S, Salamatullah HK, Alkhiri A, Faidah DE, Afif LM, Bukhari JI, Abulaban A, Al Malik Y, Levy M.
Mult Scler Relat Disord. 2024 May;85:105524. doi: 10.1016/j.msard.2024.105524. Epub 2024 Mar 1.
PMID:38479045
A case of anti-aquaporin-4 antibody-positive optic neuritis treated by selective immunoadsorption.
Naganuma T, Furusawa Y, Hanaoka A, Takemoto Y, Uchida J.
MRI characteristics of neuromyelitis optica spectrum disorder: an international update.
Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, Klawiter EC, Sato DK, de Seze J, Wuerfel J, Banwell BL, Villoslada P, Saiz A, Fujihara K, Kim SH; Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository.
Neurology. 2015 Mar 17;84(11):1165-73. doi: 10.1212/WNL.0000000000001367. Epub 2015 Feb 18.
PMID:25695963
Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders.
Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models.
Wang L, Du L, Li Q, Li F, Wang B, Zhao Y, Meng Q, Li W, Pan J, Xia J, Wu S, Yang J, Li H, Ma J, ZhangBao J, Huang W, Chang X, Tan H, Yu J, Zhou L, Lu C, Wang M, Dong Q, Lu J, Zhao C, Quan C.
Front Immunol. 2022 Mar 31;13:873576. doi: 10.3389/fimmu.2022.873576. eCollection 2022.